Ameriprise
AGN

Ameriprise’s Allergan plc AGN Stock Holding History

Ameriprise’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,500
Closed -$938K – 3871
2016
Q1 		$938K Buy
+3,500
New +$1M ﹤0.01% 2882
2015
Q3 		– Sell
-16,600
Closed -$5.04M – 4013
2015
Q2 		$5.04M Buy
+16,600
New +$4.95M ﹤0.01% 2147

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Ameriprise's AGN Position: Q2 2020 in Review

Ameriprise sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 698,128 shares — an estimated $124M sold.

Ameriprise first reported a position in AGN in Q2 2013 and held it in 28 quarters. The position peaked at $1.16B in Q3 2018. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • Ameriprise reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • Ameriprise sold 698,128 Allergan plc shares in Q2 2020, an estimated $124M.
  • Ameriprise first reported a position in Allergan plc in Q2 2013 and held it in 28 quarters.
  • Ameriprise's Allergan plc position peaked at $1.16B in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Ameriprise's 13F filing for Q2 2020, filed 14 Aug 2020.